EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy

Ido Cohen iD, Eyal Lebel iD, Sigal Grisariu, Batia Avni iD, Shlomit Kfir-Erenfeld, Nathalie Asherie, Eran Zimran, Vladimir Vainstein, Miri Assayag, Tatyana Dubnikov Sharon, Rivka Alexander-Shani, Nomi Bessig und 8 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27073113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ido Cohen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Virus Activation, B-Cell Maturation Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR-T) cell therapy has become a standard of care for many hematological malignancies, and has significantly transformed treatment outcomes. However, CAR-T therapy is associated with specific toxicities, including infections. Although the anti-CD19 CAR-T risks are well-characterized, infectious complications following B-cell maturation antigen (BCMA)-directed CAR-T in multiple myeloma (MM) remain under-researched. In this study, we evaluated the incidence and clinical impact of cytomegalovirus (CMV), Epstein–Barr virus (EBV), and adenovirus (ADV) reactivations in 75 patients receiving anti-BCMA CAR-T for MM, and compared them to 60 patients receiving commercial anti-CD19 CAR-T for B-cell lymphoma (BCL). The viral reactivation rates were 20% for CMV and 8% for EBV in the MM group, vs. 31.7% and 3%, respectively, in the BCL group. No ADV reactivations were seen in either cohort. Most of the CMV reactivations (87% in the MM cohort and 68.5% in the BCL cohort) were asymptomatic and clinically insignificant, and had no impact on progression-free survival (PFS) or overall mortality. Overall, these findings suggest that although CMV and EBV reactivations are relatively common after anti-BCMA CAR-T, they are rarely associated with meaningful disease, and the risks do not exceed those of CD19-directed therapy. Thus, routine pre-emptive screening for these viruses may be unwarranted in asymptomatic patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveVirus ActivationB-Cell Maturation AntigenReceptors, Chimeric AntigenHumansFemaleMaleMiddle AgedHerpesvirus 4, HumanAgedCytomegalovirusAdultAdenoviridae

Stichwörter der Autor:innen

B cell lymphomaBCMACAR-T-cell therapyEpstein–Barr virusadenoviruschimeric antigen receptor T cellcytomegalovirusmultiple myelomaviral reactivation

Substanzen

B-Cell Maturation AntigenReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
  • Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
  • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.

ORCID-Profile: Ido Cohen, Eyal Lebel, Batia Avni, Moshe E Gatt

Zitieren

APA

Cohen, I., Lebel, E., Grisariu, S., Avni, B., Kfir-Erenfeld, S., Asherie, N., Zimran, E., Vainstein, V., Assayag, M., Sharon, T. D., Alexander-Shani, R., Bessig, N., Shehadeh, A., Ishtay, A., Schlossberg, M., Pick, M., Gatt, M. E., Bdolah-Abram, T., Stepensky, P., & Elias, S. (2026). Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073113

Vancouver

Cohen I, Lebel E, Grisariu S, Avni B, Kfir-Erenfeld S, Asherie N, et al. Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27073113

BibTeX
@article{Cohen2026,
  author = {Cohen, Ido and Lebel, Eyal and Grisariu, Sigal and Avni, Batia and Kfir-Erenfeld, Shlomit and Asherie, Nathalie and Zimran, Eran and Vainstein, Vladimir and Assayag, Miri and Sharon, Tatyana Dubnikov and Alexander-Shani, Rivka and Bessig, Nomi and Shehadeh, Alaa and Ishtay, Aseel and Schlossberg, Miriam and Pick, Marjorie and Gatt, Moshe E and Bdolah-Abram, Tali and Stepensky, Polina and Elias, Shlomo},
  title = {Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27073113}
}
Kostenlos starten →